biochemical data were collected for four visits during 12 months of observation. Results 432 patients (mean age 50.9 ± 14.9 years) were enrolled. Of them, 247 men were receiving androgen therapy, whereas 145 were naive. After the first visit (V0), 80 men started androgen therapy, whereas 55 remained untreated during the entire observation. Younger age [odds ratio (OR) 0.57 (0.35-0.92)], total T < 8 nmol/l [OR 4.69 (1.59-13.81)], complaining at least one sexual symptom )] and reporting more severe lower urinary tract symptoms [OR 1.27 (1.01-1.60)] predicted starting an androgen therapy. Sixty-four men started therapy immediately after V0 and maintained it until the observation end. When compared to V0, they reported an increase in all the domains of the International Index of Abstract Purpose Management of late onset hypogonadism (LOH) is not homogenous. The aim of the study is to observe the management of patients with low testosterone (T) in highly specialized Italian centres. Methods The SIAMO-NOI is an observational longitudinal disease registry for the evaluation of the clinical management of patients with low T levels (total T < 12 nmol/L, calculated free T < 225 pmol/l or already in treatment) in 15 Italian centers members of the Italian Society for Andrology and Sexual Medicine (SIAMS). Clinical and Electronic supplementary material The online version of this article
Introduction
Low testosterone (T) is a frequent finding in adult men with sexual dysfunction and, in this population, its prevalence is even doubled in comparison with the general one [1] . Hence, physicians working in Sexual Medicine and Andrology frequently deal with the problem of diagnosing it, especially when developing in adulthood (late onset hypogonadism, LOH). LOH is a clinical condition whose definition is still largely debated [2] . In European community dwelling men involved in the European Male Ageing Study (EMAS), T declines with a yearly rate of 0.4 % [3] and this age-related trend is hastened by obesity and comorbidities [3] . T decline is associated with the appearance of symptoms, such as erectile dysfunction (ED), reduced sexual desire, weakness and loss of energy, and signs, such as increased fat mass, decreased bone and muscle mass, loss of body hair [4] [5] [6] [7] [8] [9] [10] . However, these symptoms and signs are not specific to LOH and are frequently found in ageing, obesity and comorbidities that, as aforementioned, are conditions often associated with T decline. This overlap in clinical features makes difficult diagnosing LOH and consequently deciding which patients can avail their selves of T replacement therapy (TRT) [11] . Available guidelines on management of LOH advice that diagnosis is based on the contemporary presence of low T levels, confirmed at least in two separate measurements, and at least one symptom related to androgen deficiency [12] [13] [14] . However, there is no agreement on the threshold of T and no clarity on which symptoms can be considered as related to androgen deficiency. According to the American Association of Clinical Endocrinologists [14] , a threshold of 7 nmol/L should be considered for diagnosing LOH, whereas the Endocrine Society [13] suggests the cut-off of 10.4 nmol/L. However, the most shared consensus [12] is that total T levels above 12 nmol/L are normal and do not require TRT, whereas total T levels below 8 nmol/L in symptomatic men deserve diagnosis of LOH and replacement therapy. Diagnosis of LOH and TRT should be considered in symptomatic men with T within 8 and 12 nmol/L, particularly when free T is below 225 pmol/L [12] . A more stringent definition of LOH has been later provided by the EMAS, which requires the contemporary presence of total T below 11 nmol/L and calculated free T below 220 pmol/L, as well as the simultaneous presence of ED, reduced morning erections and decreased sexual desire [15] . The need for a symptomatology cluster of sexual symptoms, more than only an androgen deficiency-related symptom, has been confirmed also in a population of men with sexual dysfunction [5] .
It is evident that the field is still controversial and needs further studies. In the meantime, diagnosis and treatment of LOH is not homogenous with different clinical and therapeutic managements, even in the same Country. To evaluate the management of patients with low T levels in Italian centres of Sexual Medicine and Andrology, we created a disease registry, based on clinical observation for 1 year. Decisions concerning treatment were performed as for clinical practice of each centre.
The aim of the study was to observe the management of patients with low T in highly specialized Italian centres and to observe which conditions predict the decision of starting a therapy for hypogonadism. Furthermore, we evaluated the differences in androgen deficiency-related symptoms and other clinical and biochemical parameters, between men who underwent androgen replacement and men who did not.
Methods
The SIAMO-NOI is an Italian disease registry with collection of longitudinal data of men with low T levels attending 15 high-specialized Italian Endocrinology/Andrology centres (Milan, Padua, Turin, Genoa, Pisa, Florence, Ancona, Terni, L'Aquila, Rome "La Sapienza", Rome "Tor Veragata", Bari, Cagliari, Cosenza and Catania) that are members of the Italian Society for Andrology and Sexual Medicine. The data collected have been used for the present multicentre study for the evaluation of the clinical management of patients with low T levels in Italian highspecialized Endocrinology/Andrology centers. The registry aimed at collecting clinical data on men with low T levels consulting Endocrinology/Andrology Units. Eligible patients were men aged more than 18 years, with total T < 12 nmol/L or calculated free T < 225 pmol/L or currently treated for a previously diagnosed hypogonadism. Patients with a life expectancy lower than 12 months, history of drug or alcohol abuse or with major psychiatric conditions were excluded from the observation. The
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Ethics Committee in each centre approved the registry. Patients signed an informed consent for participating the observation. Each centre was required to enroll a consecutive series of patients attending their Outpatient Clinics for endocrine, andrology or sexual conditions during a period of six months after the approval of their own Ethics Committee. Overall, the enrollment took from 1 August 2012 to 15 October 2013, when the first and the last patient of the registry were recruited.
Each patient enrolled was scheduled for four visits, performed each 4 months for an overall observation of 1 year. During the first visit (V0), socio-demographic information, medical history and medications used were registered. In addition, patients were interviewed with two structured interviews ANDROTEST [16, 17] and SIEDY [18, 19] , for the screening of hypogonadism and for the assessment of the pathogenetic components of ED (organic, relational and intra-psychic), respectively. Patients were asked to answer questionnaires concerning sexual function (International Index of Erectile Function-15: IIEF-15) [20] , lower urinary tract symptoms [LUTS; International Prostate Symptom Score (IPSS)] [21] and hypogonadism-related symptoms [Aging Males' Symptoms (AMS)] [22] . All patients underwent a complete physical examination, with measurement of blood pressure, waist circumference, height, and weight. Prostate was assessed by digital rectal examination (DRE) and testis volume using Prader orchidometer. Laboratory analyses were made using local laboratories and included fasting glucose, total cholesterol, high-density lipoprotein (HDL) cholesterol and triglycerides, total T, sex hormone binding globulin (SHBG), luteinizing hormone (LH), prostate specific antigen (PSA) and hematocrit. Free T was calculated according to the Vermuelen formula [23] . Ten-year cardiovascular (CV) risk was estimated using the Progetto Cuore risk engine [24] . At the second, third and fourth visits (V1, V2 and V3, respectively) newly occurred medical conditions or new medications since the previous visit were registered. Patients were asked to fill in IIEF-15, IPSS and AMS. Biochemical data on hematocrit, PSA, fasting glucose, total and HDL cholesterol, triglycerides, T and SHBG were also collected.
Statistical analyses
In the baseline assessment, men currently treated for hypogonadism (n = 247) and those naïve from any specific treatment (n = 145) were compared. Unpaired twosided Student's t tests were used for unadjusted comparison of means of normally distributed parameters, whereas the comparisons adjusted for confounding factors were assessed by the analysis of covariance (ANCOVA). For categorical variables, Chi squared analyses and ordinal logistic regressions were used for unadjusted and adjusted analyses, respectively. In the longitudinal evaluation, men who started a treatment for hypogonadism during the observation (treated group) were compared to those who never underwent such a therapy during the observation (untreated group). The predictor analysis was performed on 80 men who started an androgen therapy at any time-point of the observation compared with 55 men who did not start a therapy during the entire observation. Multiple regression models, adjusted for center as a random effect, were used to account for the hierarchical study design (individuals nested within center). The relationships between the therapy status and putative predictors were assessed using multilevel binary logistic regression models, where the therapy status was the outcome, with no treated group being the referent. Ten factors were included as fixed-effect predictors: age, smoking status (current smoker, yes/no), alcohol intake (≥2 drinks daily vs. less), family history of hormone dependent neoplasia (yes/no), delayed puberty [yes/no, as assessed by question #2 of ANDROTEST [16, 17] , "When did you undergo your sexual development (puberty)?" Scoring 0 = 9-14 years (normal age) or 1 ≥ 14 years (delayed)], history of pituitary diseases (yes/no, as assessed by question #3 of ANDROTEST [16, 17] , "Have you ever had a pituitary disease?" Scoring 0 = No or 1 = Yes), number of comorbidities, sexual complaints (at least one sexual symptom vs. none), IPSS total score, total testosterone levels (<8 vs. ≥8 nmol/L). For the outcome analyses, 64 men who started an androgen therapy during the period between V0 and V1 and who continued the therapy until the end of the survey were compared with 55 men who did not start a therapy during the entire observation. The outcome analyses were performed by linear mixed models (ANOVA mixed model with random intercept) for studying the variation (time effect) of clinical variables, from baseline to the end of treatment, within the groups of subjects treated and untreated. All the outcome analyses, either in the cross-sectional or longitudinal study, were adjusted for age, centre, smoking habits, alcohol intake and number of comorbidities, unless otherwise specified.
Normally distributed data were expressed as mean ± standard deviation, non-normally distributed data were reported as median (quartiles), unless otherwise specified.
All the analyses were carried out with SPSS 22 statistical package (IBM Corporation, Armonk, NY, USA) and a p < 0.05 was considered statistically significant.
Results

Baseline assessment
During the period of enrollment, 432 men were recruited ( Table 1 ). The characteristics of the sample are reported in Table 1 . Among them, 173 men were not receiving androgen therapy (with 145 naïve from any treatment and 28 reporting previous androgen therapies); 247 men were currently receiving a treatment for hypogonadism and for 12 men the information was not available. For 28 subjects who received therapy in the past, information on medications and the dose, period of treatment and time of washout was not available. For these reason, they were excluded from the analyses. Among men who reported at baseline a current therapy for hypogonadism, 24.0 % were using T gels, 41.5 % T undecanoate injectable, 9.4 % injectable T short acting, 4.9 % chorionic gonadotropin, 1.2 % mesterolone, 1.2 % T undeacanoate oral, 0.4 % a selective estrogen receptor modulator and for 17.5 % this information was not available. Supplementary figure 1 shows total and calculated free T levels according to different treatments. Men already receiving a treatment at baseline were compared with those naïve from any androgen therapy. When considering the items of SIEDY ( Fig. 1 ), after adjusting for age, centre, smoking and drinking habits and comorbidities, men currently treated had lower severity of ED, either for the difficulty in obtaining or maintaining an erection. Furthermore, they reported greater frequency of morning erections and sexual desire (Fig. 1) . No difference was found between treated and untreated men concerning ejaculate volume, quality of erection during masturbation and orgasm difficulties (Fig. 1 ). Among the items evaluating the marital relationship, a significant difference was reported only for patient's perception of his partner's orgasm and, in particular, men currently treated perceived a better orgasmic function in their partners. Concerning the IIEF-15 questionnaire, treated men scored higher in the domains dealing with erectile function, desire and overall satisfaction, as well as in the IIEF-15 total score, even after adjusting for the aforementioned confounders (Fig. 2) . When considering the items of the AMS questionnaire, treated men reported less often lack of vitality, reduced muscle strength, beard growth, frequency of sexual activity or morning erections and sexual desire (Fig. 3a) . Accordingly, the AMS sexual subscale was significantly lower in treated than in untreated men, whereas no significant difference between the two groups was found in the physical and psychological symptoms subscales ( Fig. 3b-d ).
Longitudinal assessment
Among the 432 subjects enrolled on the SIAMO-NOI registry, 373, 346 and 381 attended V1, V2 and V3, respectively. Of 373 men enrolled who attended V1, 344 attended also V2 and 329 attended all the four scheduled visits. During the 12 months of observation, 192 men reported a continued androgen treatment throughout the observation, whereas 9 discontinued therapy in the period between V0 and V1, 7 in the period between V1 and V2 and 8 during the period between V2 and V3. An androgen therapy was initiated between V0 and V1 in 64 subjects, between V1 and V2 in 13 men and between V2 and V3 in 3 men. Fiftyfive men did not start a therapy during the observation, thus remaining naïve from androgen therapy. Twenty-five men did intermittent use, and in 56 subjects the information was not reported. The following analyses compared the group of patients who started an androgen therapy during the observation with those who did not (see "Methods" section). The characteristics of the patients enrolled in the registry but not included in the following analyses, due to their androgen therapy status, are reported in Supplementary Table 1 . Table 2 shows total and calculated free T in men who did not start any therapy for hypogonadism and in men who started a therapy at the beginning of the observation and continued it until the last follow-up visit. Multiple regression analysis considering the candidates predictors of starting therapy, adjusted also for center, showed that younger patients, those reporting at least one sexual symptom and those with baseline total T levels below 8 nmol/L were more probably prescribed for an androgen therapy (Fig. 4) . Quite surprisingly, complaining more severe LUTS, as assessed by a greater IPSS score, was associated with a higher probability of starting a therapy for hypogonadism (Fig. 4) . Among the treated subjects, 92.4 % complained at least one sexual symptom, meeting the criteria for staring a replacement therapy. Among the untreated men, 74.5 % reported at least one sexual symptom, thus being possible candidates to a replacement therapy, according to the guidelines.
We did not observe any difference in IIEF-15 subscale scores at baseline between patients who started an androgen therapy between V0 and V1 and maintained it for the rest of the observation (treated group) and those who did not (untreated group), except for the desire subdomain, which was significantly lower in the former group (Table 3) . The comparisons between groups according to having or not therapy (Table 4) showed a significantly greater improvement in all the IIEF-15 subscales in the treated group. Figure 5 shows the within group comparisons. Concerning the erectile function subdomain of the IIEF-15 (IIEF-EF), an increase in the score in comparison to V0 was reported from the V1 and maintained until V3 in both the groups (Fig. 5a) . A similar trend of improvement was observed in all the other subscales (orgasmic function, desire, intercourse satisfaction and overall satisfaction; Fig. 5b-e) only in the treated group. The IIEF-15 total score increased from V1 to V3 in treated men, whereas in those untreated a marginal, but significant, improvement was observed only at the last visit (V3) (Fig. 5f ). Consistently with the results from the IIEF-15, the AMS sexual subdomain showed a greater improvement in the androgentreated group than in the untreated one (between group comparisons; Table 4 ). Although score changes from V0 were detectable in both groups from V1 until V3 (within group comparisons; Fig. 6a ), they were more apparent in the treated group. A greater improvement in treated men was also detected for the AMS physical subdomain (between group comparisons; Table 4 ). Similar to the other scores, the improvement in this subdomain was detectable from V1 until V3 in the treated group (within group comparisons; Fig. 6b ). No significant change from the baseline value was found for the AMS psychological subdomain (Fig. 6c) .
Concerning the metabolic parameters, the treated and the untreated groups were not different at baseline (Table 3) and did not differ by the time in any parameter (between group comparisons; Table 4 ). In the untreated group, waist circumference at V1 and V2 was significantly higher than V0 (Table 2) , whereas, in the treated group there was a numeric trend towards reduction, which did not reach statistical significance. In treated men total cholesterol was Table 2 Comparisons within groups of subjects who did not start an androgen therapy and those who started an androgen therapy at the beginning of the observation and maintained it until the last follow-up visit Data are derived from linear mixed models and are adjusted for age, centre, smoking habits, alcohol intake and number of comorbidities Data are expressed as mean and 95 % confidence interval. For non-normally distributed parameters, the log-transformed value is reported * p < 0.05 versus baseline; ** p < 0.01 versus baseline; **** p < 0.0001 versus baseline a Only adjusted for centre, alcohol intake and number of comorbidities
No androgen therapy 8.4 (6.9-9.9) 9.9 (7.7-12.1) 9.3 (7.6-11.0) 9.5 (7. Table 4 ). However, in the treated group a significant decline at V3 was observed as compared to baseline (Table 2) . Hematocrit, not different at baseline (Table 3) , increased by the time only in the treated group (between group comparisons; Table 4 ). Accordingly, as compared with V0, men treated with androgens, had greater hematocrit at all follow-up visits (Fig. 7) . During the entire observation, few cases of polyglobulia occurred (4 at V0, 3 at V1, 5 at V2 and 4 at V3) and the prevalence in the two groups was not different at any time-point.
At baseline, PSA levels were similar in the two groups (Table 3 ) and they did not change significantly during the entire observation in both groups (Table 4 and Fig. 7) . PSA ≥ 4 ng/ml was achieved by few patients (3 at V0, 3 at V1, 5 at V2 and 4 at V3), without a different prevalence in the two groups at each time-point.
The change in IPSS during the observation was not different in the treated and the untreated group (between group comparisons; Table 4 ). However, in men treated with androgens, the IPSS score at V3 was significantly lower than at V0 (Fig. 7) .
Discussion
In a context of uncertainty concerning the definition and the clinical management of LOH, physicians that work in a specialized andrologic setting-such as those of medical centers affiliated to the Italian Society of Andrology and Sexual Medicine-are more likely to prescribe an androgen therapy in particular conditions. In fact, younger men, those with total T below the strictest threshold identified by the guidelines, those reporting sexual symptoms and those with more severe LUTS were more likely receiving treatment. We here report that hypogonadal men during 1 year of treatment with androgens improved more often their sexual and physical symptoms than those untreated. A therapy-related improvement in LUTS was also observed at the end of the observation, whereas other metabolic advantages were not statistically significant, apart from a reduction in total cholesterol. Waist circumference increased in untreated subjects, but not in the treated ones.
The decision of starting TRT in men with T < 8 nmol/l mirrors the guidelines on diagnosis and treatment of LOH [12] [13] [14] that substantially agree on the appropriateness of treating men with total T below these values without any further biochemical analysis. Consistent with the guidelines and the most recent literature on this topic, Italian andrologists choose to treat symptomatic men. Several symptoms have been associated with low T in epidemiological studies [4, 5, 15, 25, 26] , however, the overlap with those related to ageing makes difficult recognizing LOH [23] . Crosssectional and longitudinal data from the EMAS study [4, 15] show that sexual symptoms are the most specific to low T levels. According to the EMAS definition [15] , their clustering, more than the presence of a single symptom, along with low T levels can identify LOH and consequently Fig. 4 Predictors of starting an androgen therapy during the observation. Data are derived from multilevel binary regression models, using centre as a random-effect covariate and age (as continuous variable), smoking status (current smoker, yes/no), alcohol intake (≥2 drinks daily vs. less), family history of hormone dependent neoplasia (yes/no), delayed puberty (yes/no), history of pituitary diseases (yes/ no), number of comorbidities, sexual complaints (at least one sexual symptom vs. none), IPSS total score (as continuous variable) and total testosterone levels (<8 nmol/L vs. ≥8 nmol/L) as fixed-effect predictors. Men starting an androgen therapy during the observation were compared with those who did not (referent category). The odds ratio and 95 % confidence intervals are expressed in a log-scale. IPSS: International Prostate Symptom Score. *p < 0.05; **p < 0.01 men who deserve treatment. These findings, derived from general population, have been confirmed in a population of men consulting for sexual dysfunction, in whom a better performance in detecting low T levels is shown by the simultaneous presence of severe impairment in morning erections and low sexual desire [5] . Interestingly, in the present study desire is the only symptom that differentiates men who start androgen therapy from those who do not, thus suggesting that it is an important parameter for physicians for prescribing TRT in men with low T levels.
Another factor involved in the decision of starting therapy in men with low T is age. Physicians working in Italian Andrology units are more likely to prescribe a therapy for hypogonadism in younger patients. The rationale and the safety of using TRT in elderly men is now strongly debated [27] . Recently, the Food and Drugs Administration released a drug safety communication on the use of T products, warning Health Care professionals on the use of T medications in men whose T decline is not due to apparent reasons other than aging [http://www.fda.gov/Drugs/DrugSafety/ucm436259.htm; 24]. This communication arises from the publication over the last 2 years of two articles showing an increased CV risk in men undergoing TRT [28, 29] . Leaving apart the specific limitations of these studies that can cast doubt on the validity of their results [27] , both of them found an increased incidence of CV events in elderly and/or frail men treated with TRT. In fact, Vigen et al. [28] conducted a retrospective study on 8709 veterans needing to undergo coronary angiography, a category that is per se at high CV risk. Similarly, Finkle et al. [29] in their retrospective assessment found an increased incidence of myocardial infarction in men older than 65 years and even in those younger than 65 years but with a prior history of heart disease. A previous randomized placebo-controlled clinical trial [30] , aimed at evaluating the efficacy of TRT in improving muscle strength in a population of institutionalized elderly men with limited mobility, was consistent with these data in fact, the study was prematurely discontinued due to the significant greater incidence of CV events in the active treatment arm. Overall, these data caution about the use of TRT in elderly men and, as the FDA underlined, point the attention on the need for high quality clinical trials specifically designed for addressing the question whether TRT is harmful for elderly and frail men. In almost 1700 subjects with ED, a population that is enriched in CV risk, low T levels did not predict forthcoming MACE, but they were associated with an increased MACE lethality [31] . Low T became even protective for forthcoming MACE when only obese men [32] or those with a prior history of MACE were considered [33] , thus suggesting that T deficiency is a mechanism for sparing energy in poor health conditions. According with this view, TRT may be even detrimental in frail men, such as the elderly. However, the meta-analysis of the available randomized clinical trials showed that, not only TRT is not associated with incident MACE in elderly, frail or CVD men, but it is even protective in subjects with metabolic diseases [34] [35] [36] . It is clear that the field is still open to discussion and needs further studies. Although in this debate the European Medical Agency (EMA) in its position statement (http:// www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Testosterone-containing_medicines/ human_referral_prac_000037.jsp&mid=WC0b01ac05805 c516f) expressed substantial reassurance for the use of TRT because to date "no consistent evidence of an increased risk of heart problems with testosterone medicines" has been provided, Italian andrologists seem to be precautionary and prefer to start therapy in younger men. Quite surprisingly, having more severe LUTS, as captured by a higher IPSS score, is an independent predictor for Italian andrologists to prescribe an androgen therapy. Despite for long time T has been believed as detrimental for prostate for its putative role in inducing/worsening benign prostate hyperplasia (BPH)/LUTS, recent data are reversing this paradigm [37] . BPH/LUTS is now recognized as a chronic inflammatory process arising from a deregulation of local immune response resulting in hyperplasia and remodeling [38, 39] . In animal models of hypogonadism surgically [40] [41] [42] [43] or metabolically [44] induced, prostate was characterized by inflammatory features and T treatment was able to counteract inflammation. Although the precise mechanism by which T mediates immunomodulation is still unclear, its anti-inflammatory effect on CD4+ T cells [45] [46] [47] and suppressing role on antigen presenting cells [46] has been reported in different autoimmune diseases. In vitro studies in human prostate cells confirmed the antiinflammatory effect of androgens [48] . Hence, these data, recognized by Italian andrologists, not only do not support a cautious attitude for TRT in BPH men but they also encourage the correction of hypogonadism in these subjects, as recently reported by the recommendations on TRT of the Italian Society of Endocrinology [49] . Accordingly, in the SIAMO-NOI registry, PSA levels did not change in men undergoing therapy and a significant improvement of IPSS score was found at the end of the period of observation.
In this sample of hypogonadal men, those who started a treatment and continued it until the end of the observation reported a significant improvement in all sexual domains. The role of TRT in improvement of sexual function has been evaluated in several placebo-controlled randomized clinical trials with conflicting results. The most recent meta-analysis of the available RCTs on this topic [50] , substantially in line with a previous one [51] , found a significant effect of T therapy, as compared with placebo, in improving erectile function, as well as other sexual domains, such as sexual desire, morning erections, sexual satisfaction and orgasmic function only in men with low T levels at registry entry. In both the meta-analyses [50, 51] , the effect of the improvement in erectile function and sexual desire was greater when T levels at baseline were lower. In the present study, erectile function, but not the other sexual domains improved during the observation also in the untreated group, although to a lesser extent than the treated ones. This result could be, at least in part, explained by the use of other therapies, such as PDE5 inhibitors, which are per se associated with an increase in T levels [52, 53] or by a sort of "placebo effect"-that is highly reported in ED therapy [54] -played by the simple fact of undergoing medical consultation and care. Fig. 7 Safety parameters in subjects who started androgen therapy immediately after V0 and maintained it until the end of the observation versus those who did not start a therapy. Data are adjusted for centre, age, smoking-drinking habits and comorbidity and reported as mean and 95 % confidence interval. PSA prostate specific antigen, IPSS international prostate symptom score. *p < 0.05; ****p < 0.0001 versus the score at V0 within the single groups Men who started androgen therapy experienced an improvement in physical function early during the observation. An improvement in subjective perception of vigour has been reported in a study with a similar design, the International Post-Authorisation Surveillance Study (IPASS), a prospective multicentre observational study on 1493 hypogonadal men treated with injectable T undecanoate [55] . The subjective perception of increased muscle strength is substantiated by the documentation in several studies of a change in body composition upon TRT, with an increase in fat free mass and a decrease in fat mass [56] . Nonetheless, an objective improvement in muscle strength has not been consistently reported. A meta-analysis of the RCTs on this topic [57] showed a heterogeneous effect of TRT on muscle strength, with a trend towards improvement only for lower limb and handgrip of the dominant arm.
The SIAMO-NOI registry did not show any change in metabolic parameters, except for a slight and not sustained increase in waist circumference in the untreated group and decrease in total cholesterol in the treated group. It should be recognized that the time span of observation was relatively short and possible effects might be evident after more than 1 year of therapy. Furthermore, the population studied, except for a high prevalence of obesity, had mean metabolic values within the normal range and this makes difficult to observe further improvements. In fact, in two meta-analyses [58, 59] , TRT demonstrated an effectiveness in improving metabolic parameters as compared with placebo, but the population enrolled was composed by men with metabolic syndrome or type 2 diabetes. Despite the non-significant change in metabolic parameters, CV risk, as estimated by the Progetto Cuore algorithm, tended to decrease in the group of men who started therapy, with a change that achieved the significance at the last follow-up visit versus the baseline.
Limitations of the present study are represented by the small sample size and the relatively short time of observation. Furthermore, the observational design has several intrinsic limitations. Firstly, it does not allow establishing a robust and clear cause-effect relationship between androgen therapy and the outcomes. In addition, the decision of starting an androgen therapy made according to physicians and patients decisions can create selection bias that cannot be completely overcome by adjusting the analyses for appropriate confounders.
Conclusions
The present study shows that the management of hypogonadal men in Andrology centers affiliated to the Italian Society of Andrology and Sexual Medicine is in line with the international guidelines. Furthermore, Italian andrologists are updated and correctly adopted the newest knowledge about the role of T on prostate health.
TRT, when adequately prescribed, is associated with an improvement in all the aspects of sexual life as well as in the perception of physical strength.
